LM

Lalit Mohan

Director Director DIN 01050128
DIN 01050128 First appointment Dec 2006 Primary industry Healthcare
Unlock full profile Investments · shareholding · contact details
Past companies 2 historical roles
Total affiliations 2 Since Dec 2006
Shareholding value •••• Premium profile

About Lalit Mohan

Data last updated:

Lalit Mohan was a Director at Curewel Biotech Private Limited (2006–2010) and Director at Antek Drugs Private Limited (2007–2015). The companies operate in Healthcare.

DIN 01050128
Primary Designation Director
Industry Healthcare
First Appointment 29 Dec 2006

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Curewel Biotech Private Limited U85120DL2006PTC157196
Director29 Dec 20062006Strike Off
Antek Drugs Private Limited U24232DL2001PTC111537
Director30 Mar 20072001Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Curewel Biotech Private Limited
Antek Drugs Private Limited
Premium access

Shareholding and investment profile for Lalit Mohan

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Lalit Mohan

Lalit Mohan was first appointed on 29 Dec 2006 as Director at Curewel Biotech Private Limited. The most recent appointment on record is 30 Mar 2007 at Antek Drugs Private Limited.

Lalit Mohan held 2 earlier board appointments: Curewel Biotech Private Limited (Director, 29 Dec 2006 to 02 Apr 2010); Antek Drugs Private Limited (Director, 30 Mar 2007 to 24 Feb 2015).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available